21 CFR 1271 HCT/P readiness: a record handoff and retrieval guide

Can your team reconstruct why an HCT/P became available for distribution when its supporting records sit in two locations—and one record cannot be found? This guide turns that question into a practical handoff and retrieval exercise for quality, processing, storage and distribution teams. Use the 21 CFR 1271 framework glossary for definitions; use this guide to test the connections between activities, evidence and decisions.

The exercise date is October 16, 2026. Juniper Tissue Operations received four separately identified units from fictional Fern Recovery on September 1. All relate to donor code DN-K73. Juniper subsequently sent them in quarantine to Alder Processing, a contracted processor, storage establishment and distributor. Juniper retained responsibility for determining availability for distribution. Three units were later distributed; the fourth remains quarantined.

Use exactly two record locations: Juniper’s records office and Alder’s manufacturing vault. Juniper holds the donor determination, release decisions, code crosswalk and copies of consignee correspondence. Alder holds processing, equipment, storage and shipment records. Incoming records from Fern are filed at Juniper. The challenge is not to collect every document into a presentation: it is to show which record supports each conclusion and what remains unknown.

• Starting evidence: receipt RC-18, four units, supplier codes FR-Q714-01 through FR-Q714-04.
• Working codes: JT-R682-01 through JT-R682-04; no units are split, pooled or added during the exercise.
• Deliberate gaps: equipment cleaning record CL-905 cannot be retrieved, and unit 02’s administration or final disposition remains unconfirmed.
• Required exercise output: a reconciled unit ledger, dated evidence requests, a human risk assessment, separate reporting decisions and a retention worksheet.

Record the applicability decision before borrowing this workflow. Under §1271.10(a), all four conditions—not merely minimal manipulation—must be met for regulation solely under section 361 and Part 1271. The evidence prompts below are suggested ways to organize that assessment.

If an HCT/P fails §1271.10(a) and no §1271.15 exception applies, §1271.20 places it under applicable drug, device and/or biological-product authorities. That is not an automatic conclusion that a section 351 biologics license application is the route. Applicable requirements include the referenced relationship to Subparts C and D.

Also record the reproductive limitation: except for §§1271.150(c) and 1271.155, Subpart D is not being implemented for reproductive HCT/Ps described in §1271.10 and regulated solely under section 361. The nonreproductive exercise below should therefore not be applied wholesale to a reproductive operation.

Section 1271.150(c) ties applicable CGTP obligations to the operations an establishment performs. A contracted establishment is responsible for requirements applicable to its manufacturing step. The establishment engaging it must ensure applicable CGTP compliance before the arrangement, take reasonable steps when information suggests noncompliance, and terminate the arrangement if it determines the establishment is not compliant.

Separately, the establishment that determines all release criteria are met and makes the HCT/P available must review manufacturing and tracking records—even when another establishment physically distributes it. Section 1271.270(e) requires the name, address and responsibilities of establishments performing manufacturing steps for you to be maintained and available for inspection.

For an establishment subject to Part 1271 registration, the current operational starting clock in §1271.21 is registration and listing within five days after beginning operations. Annual registration updates occur in December, subject to the section’s stated exception. Listing updates follow the change/no-change branches: no specified change means no listing update is required; a specified change is reported at the time of change or in the first June or December after it. Section 1271.22 requires electronic registration and listing.

As a practice, compare the activity worksheet with the submitted listing: §1271.25(b) covers HCT/Ps recovered, processed, stored, labeled, packaged, distributed, or subject to donor screening or testing, and asks whether each meets §1271.10. Keep the comparison separate from release evidence. FDA acceptance of registration and listing does not establish compliance or mean the HCT/P is licensed or approved.

Under §1271.265(a), evaluate each incoming HCT/P for the presence and significance of microorganisms, inspect for damage and contamination, and decide whether to accept, reject or quarantine it against pre-established criteria designed to prevent communicable disease transmission. Section 1271.265(e) requires documentation of identity and supplier, activities and results, dates, quantity and disposition.

In the fictional RC-18 record, Juniper documents receipt on September 1 of all four supplier-coded units, the receipt evaluation and inspection results, and a quarantine decision because donor eligibility is incomplete. The result is not simply ‘shipment received.’ It identifies the criteria applied and links the resulting custody and status entries. The exercise assumes no adverse receipt finding; it does not prescribe a test panel.

Section 1271.270(a) requires concurrent records that identify the person performing the work and entry dates, with enough detail to reconstruct the work and relate it to the particular HCT/P. For this exercise, add the operator, criterion revision, quantity unit and linked record references. Those field names are design suggestions; the underlying record requirements do not mandate this screen layout.

Quarantine under §1271.3(q) may use a clearly identified physically separate area or other procedures, such as automated designation, to prevent improper release. In the exercise, physical location Q-J1 and the recorded quarantine status agree. Ask another participant to explain the status without relying on a color alone.

Under §1271.50, the responsible establishment determines donor eligibility from the required screening and testing, and a responsible person determines and documents eligibility. In this case, fictional responsible person Noor Ellis records an eligible determination in DE-12 on September 4. That changes the donor-decision status; it does not complete processing, resolve packaging departures or authorize distribution.

After the determination, §1271.55 requires the distinct container code, eligible/ineligible statement and summary of determination records to accompany the HCT/P at all times. The summary includes the specified laboratory-certification statement, listing and interpretation of communicable disease test results, and name and address of the determining establishment; an applicable ineligible-donor release also needs the specified reason statement. Retained determination documentation includes the responsible person’s name and determination date.

Preserve the privacy distinction. Section 1271.55(a)(1) qualifies the prohibition on names, social security numbers and medical record numbers in the identification code for autologous donations, directed reproductive donations and first- or second-degree blood-relative donations. Section 1271.55(c) separately prohibits donor names or other identifying personal information in the accompanying records. For this fictional unrelated, nonreproductive case, use only the tracking codes in the handoff packet.

Exception pathways need their own documented handoff

• Incomplete determination, §1271.60: keep the HCT/P quarantined, including during shipment. The urgent-medical-need pathway requires documented urgent need, the labels ‘NOT EVALUATED FOR INFECTIOUS SUBSTANCES’ and ‘WARNING: Advise patient of communicable disease risks,’ completed screening/testing results and a list of unfinished items. The manufacturer documents physician notification, completes the determination during or after use and informs the physician of the result. Urgent need means no comparable HCT/P is available and the recipient is likely to suffer death or serious morbidity without it.
• Ineligible donor, §1271.65: the limited-use circumstances are allogeneic use in a first- or second-degree blood relative, directed reproductive donation, or documented urgent medical need. Applicable controls include the Biohazard legend, patient-risk warning, reactive-result warning when applicable, §1271.55 records and documented physician notification of screening/testing results. Prevent improper release during storage or identification of these HCT/Ps.
• Donor exceptions, §1271.90: use the exact applicable exception and labeling provisions, including the conditions for specified cryopreserved reproductive donations. For autologous storage, the rule specifies ‘FOR AUTOLOGOUS USE ONLY.’ An exception is not an instruction to mark an unperformed donor determination ‘eligible.’

None of those exception pathways is invoked in this case. For a fuller donor-record workflow, use donor eligibility, lookback and deviation readiness; keep this exercise focused on the receiving establishment’s evidence handoff.

A rule that treats every movement as released distribution obscures §1271.265(b). When an HCT/P is not available for distribution, shipment within or between establishments requires you first to determine and document whether pre-established criteria designed to prevent communicable disease transmission have been met, and shipment in quarantine. This is distinct from availability for distribution under §1271.265(c).

On September 2, before DE-12 exists, Juniper records predistribution shipment QS-22 for all four units to Alder. The packet documents the applicable shipping criteria and their satisfaction. Because donor eligibility is incomplete, §1271.60(c) also requires accompanying donor identification, a statement that the determination is incomplete, and a statement prohibiting implantation, transplantation, infusion or transfer until completion except under the urgent-need provision.

Section 1271.265(d) requires packaging and shipping containers that protect against contamination and established shipping conditions for each HCT/P type. In the exercise, link those conditions and transit evidence to QS-22 rather than substituting a carrier delivery receipt for the shipping assessment. Alder’s QR-19 confirms quantity, identity and receipt findings without rewriting Juniper’s earlier decision.

Section 1271.180 requires appropriate procedures for performed steps, responsible-person review and approval before implementation, and availability to personnel where operations occur or nearby when necessary. Section 1271.220 requires processing that prevents contamination, cross-contamination and communicable disease transmission. Cells or tissue from two or more donors must not be pooled during manufacturing, and in-process HCT/Ps remain controlled until required inspections, tests, verification or documented approvals are complete.

Alder’s fictional processing record PR-64 covers September 5 and identifies all four units separately. It references procedure PRC-8 revision 3, its preimplementation approval, the personnel performing the work, equipment EW-6 and the applicable in-process evidence. No splitting or quantity conversion occurs. Unit 04 has packaging departure DP-14, recorded that day; it is not silently removed from the four-unit history.

For storage, §1271.260 requires controls against mix-ups, contamination, cross-contamination and improper availability. It requires appropriate temperature, established acceptable temperature limits at each manufacturing step, recorded temperatures and periodic review. Corrective action must be taken and documented when proper storage conditions are not met. Expiration, where appropriate, depends on HCT/P type, processing, storage conditions and packaging.

The fictional storage record ST-44 links all four units to storage equipment ST-2, the approved limit specification and recorded conditions during their respective occupancy periods. All have an assigned expiration date of August 31, 2027, solely as an exercise assumption. No numerical temperature limit is supplied here. Ask participants to retrieve the actual specification reference and review evidence, not infer suitability from an alarm-free dashboard.

An effective practice is to compare three things together: where a unit was, which procedure applied at that time, and which contemporaneous measurements support the conclusion. A complete temperature graph with an uncertain unit-location interval is still an unresolved evidence connection.

Section 1271.200 requires appropriately designed equipment, valid results from inspection/measuring/testing equipment, scheduled cleaning, sanitizing and maintenance, routine inspection, and calibration where appropriate. Records cover those activities and equipment use, including identification of each HCT/P manufactured with the equipment. Recent activity records must be displayed on or near the equipment or readily available to the relevant personnel.

Do not describe every software check as validation. Under §1271.160(d), custom software or commercially available software customized or programmed for a core-CGTP function must have its performance—and changes—validated for intended use when relied upon for core CGTP compliance. Other software relied upon for that compliance must have performance verified for intended use. These activities and results must be approved and documented before implementation.

For each software item, add the version used, the function relied upon, the owner and the approved evidence reference. In the fictional setup, the software evidence predates operational use. A vendor description, a successful login or a current screenshot is not the exercise’s substitute for the establishment’s intended-use evidence. The table describes evidence to retrieve, not a claim that any named commercial platform has fulfilled these duties.

Before making an HCT/P available, §1271.265(c)(1) requires review of its manufacturing and tracking records and verification and documentation that release criteria have been met. A responsible person must document and date the availability determination. Section 1271.3(t) defines that person by authorization, training and qualification for designated functions—not by a particular job title.

The rule prohibits making available an HCT/P in quarantine, contaminated, failing release criteria, or from an ineligible or incompletely evaluated donor except under the specified §§1271.60, 1271.65 and 1271.90 provisions. A relevant procedural departure also requires a responsible-person determination that it does not increase communicable disease risk; the departure must be recorded and justified when it occurs.

In fictional RR-31, responsible person Leena Orr documents the September 9 review and availability of units 01–03. The review identifies DE-12, the manufacturing and storage records, the code crosswalk and applicable release criteria. It references CL-905 as reviewed at Alder on that date. Unit 04 is explicitly excluded because DP-14’s packaging assessment is unresolved; no no-increased-risk determination has been made for that departure.

• Record the exact units and quantities covered: three available, one still quarantined.
• Distinguish a criterion verified from a document merely received.
• Identify the reviewed record versions or dated records, including remotely held evidence.
• Keep the unit 04 assessment open with its owner and requested evidence; do not backdate a later decision.

The later inability to retrieve CL-905 does not prove that it never existed. Equally, its citation in RR-31 does not replace the missing record. The exercise must preserve both facts: a dated review was recorded, and supporting evidence is now unavailable for follow-up evaluation.

Section 1271.290 requires establishments handling HCT/Ps during manufacturing to track them from donor to consignee or final disposition and back. The distinct code links the HCT/P to its donor and records. An establishment may adopt an existing code or assign a new one, but a new code requires procedures relating it to the old code. Except as described in §1271.55(a)(1), tracking codes must not contain a person’s name, social security number or medical record number.

Juniper’s fictional crosswalk CW-17 pairs each FR-Q714 suffix with the matching JT-R682 suffix and donor DN-K73. Alder records distribution by the new code and HCT/P type. Section 1271.290(f) requires written notice to the consignee, at or before distribution, of the tracking requirements and the established tracking system. The exercise files copies of those notices with the distribution records.

For returns, §1271.265(f) requires procedures to determine suitability for return to inventory. No unit is returned in this case. If a participant adds a return, add the corresponding evidence and update quantities rather than treating a carrier return scan as an inventory decision.

Section 1271.270(b) requires a records system that supports preavailability history review and subsequent follow-up or investigation. When records are held in multiple locations, the system must ensure prompt identification, location and retrieval of all records. The regulation permits electronic records, original paper and true copies; electronic records must be backed up, and equipment needed to make records available and legible must be readily available.

1. Give the retrieval team only JT-R682-02 and the October 16 exercise date. Ask it to identify the supplier code, donor code, quantity and last supported custody event.
2. Retrieve CW-17, RC-18, QS-22, QR-19 and DE-12. Confirm the sequence distinguishes quarantined movement from the later donor determination.
3. At Alder, retrieve the applicable procedure, PR-64, EU-64 and ST-44. Request CL-905 by its exact reference and date.
4. Compare RR-31’s review references with the records actually retrievable now. Record CL-905 as missing; do not recreate it from the review checklist.
5. Follow unit 02 to Elm and then run the reverse trace from Elm’s receipt record to DN-K73. Expand to all four units associated with that donor and the EW-6 use interval.
6. Reconcile four received = three distributed + one quarantined. Within the distributed group, distinguish one known administration, one documented disposal and one unresolved subsequent status.

Record actual retrieval start and completion times if useful, but set no universal performance promise. Score separately whether identity was reconstructed, the evidence was available, the conclusion was supported and the unresolved item had an owner. A fast search that returns an unsupported ‘complete’ status is not a successful exercise.

At the stopping point, preserve the unresolved findings. The packet can be useful without being complete: it identifies three distributed units potentially relevant to the equipment-record investigation, one quarantined unit and the precise information still needed. Do not invent recipient clinical details to fill the tracking gap.

Under §1271.160, the quality program investigates and documents core-CGTP deviations and trends, evaluates causes and corrective actions, and verifies corrective-action effectiveness. Its procedures also address possible contamination or communicable-disease information, information sharing, risk assessment and appropriate follow-up, including notification, quarantine, recall and reporting as necessary. Investigation should not be reduced to the question ‘Is an FDA report required?’

For the reporting branches below, first apply §1271.330: this subpart is implemented for nonreproductive §1271.10 HCT/Ps regulated solely under section 361 and their manufacturers. Drug, device and section 351 biological-product HCT/Ps are not subject to this subpart. These are Part 1271 reporting clocks, not Part 606 blood clocks.

The adverse-reaction arithmetic cards are separate hypothetical exercises, not additional facts in the four-unit case. In the actual fictional retrieval case, no adverse reaction has been supplied. The missing cleaning record triggers assessment, not an automatic declaration of contamination or reportability. Section 1271.3(dd) covers deviations from applicable requirements, standards or specifications relating to disease transmission or contamination, and unexpected events that may relate to transmission or lead to contamination.

Complete the investigation worksheet with the event and discovery date, potentially affected units, performed or contracted step, relevant core requirement, available evidence, uncertainties, immediate risk actions, reporting rationale and decision owner. For CL-905, assess all four EW-6-linked units, including the three already distributed. Preserve October 16 as the discovery date under evaluation; do not move it to the day the investigation closes.

The exercise ends with reportability unresolved pending assessment, not with an unsupported ‘not reportable.’ Assign prompt follow-up and track the applicable deadline while the assessment proceeds. Document any notifications or other risk actions separately from the eventual reporting determination.

Section 1271.270(d) sets a default of ten years after record creation unless otherwise stated. Records pertaining to a particular HCT/P must instead be retained at least ten years after administration. If administration is unknown, use at least ten years after the latest of distribution, disposition or expiration. Section 1271.55(d)(4) gives the same particular-HCT/P timing for the required donor records. Do not substitute ‘ten years after release’ or ‘administration or expiration, whichever is later.’

As a records-management practice, identify shared supporting records and preserve them for all applicable linked record sets. A single cleaning or processing record may support several units with different clocks. Record the chosen trigger, supporting evidence, calculation and reason for any provisional value. Review unresolved dates before authorizing disposal of records.

Close the exercise with a dated findings packet, not a blanket compliance score. It should contain the four-unit reconciliation, the old/new code relationships, the quarantined shipment record, the separate donor and availability decisions, the evidence actually retrieved, the CL-905 search request, unit 02’s status request, DP-14’s owner, reporting assessments and retention calculations. Set a follow-up exercise that tests the repaired retrieval route and the effectiveness of the corrective action rather than merely confirming that a new procedure was issued.